Clinical Trials
43 trialsLutécio
Instituto do Cancer do Estado de São Paulo
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors
Oscotec Inc.
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
Jonsson Comprehensive Cancer Center
Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer
Tufts Medical Center
Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer
Emory University
HS-10502
Jiangsu Hansoh Pharmaceutical Co., Ltd.
IVY
Eli Lilly and Company
Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer
University of California, San Diego
DOP
The Netherlands Cancer Institute
Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer
Medical University of South Carolina
Radiation Therapy, Docetaxel, and Hormone Therapy in High-Risk Locally Advanced Metastasized Prostate Cancer
University of Nebraska
OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors
Canadian Cancer Trials Group
A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies
AstraZeneca
Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer
Weill Medical College of Cornell University
Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Ketoconazole Plus Docetaxel to Treat Prostate Cancer
National Institutes of Health Clinical Center (CC)
LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel
Hackensack Meridian Health
Pilot Study of Mobilization and Treatment of Disseminated Tumor Cells in Men With Metastatic Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer
M.D. Anderson Cancer Center
Pazopanib, Docetaxel, Prednisone Prostate
Duke University
Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer
Medical University of South Carolina
Docetaxel and Lycopene in Metastatic Prostate Cancer
Medical University of South Carolina
S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors
SWOG Cancer Research Network
Phase I Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer
Stanford University
Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies.
University of Michigan Rogel Cancer Center
Study of Lenalidomide and Docetaxel in Subjects With Androgen Independent Prostate Cancer
Columbia University
Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors
University of Arizona
A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer
Bastyr University
Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients
AmpliMed Corporation
Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors
Mirati Therapeutics Inc.
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
National Cancer Institute (NCI)
A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer
Centocor, Inc.
A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given With a Fixed Dose of Docetaxel and Prednisone in Patients With Metastatic Prostate Cancer
Synta Pharmaceuticals Corp.
Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer
National Cancer Institute (NCI)
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
Dartmouth-Hitchcock Medical Center
Estramustine, Docetaxel, and Carboplatin in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
National Cancer Institute (NCI)
Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC
AstraZeneca
Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer
Emory University
A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies
GlaxoSmithKline
ZANTE
National Cancer Institute, Naples
Tax-Sam
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Bi-Weekly Administration of Docetaxel for Older Men With Hormone Refractory Prostate Cancer
Geriatric Oncology Consortium